Aeropay | $20,000,000 | (May 17, 2024)
Bedrock Materials | $9,000,000 | (May 17, 2024)
OTPLESS | $3,500,000 | (May 17, 2024)
Certified by Founder
Lodge
Proniras Corporation
start up
United States
- Seattle, Washington
- 02/02/2024
- Series B
- $4,650,000
Proniras Corporation is a clinical-stage biotechnology developing novel small-molecule therapeutics for the treatment of substance use and specialty central nervous system disorders. The Company’s lead program PRN-001-01 (tezampanel) is being clinical developed as a treatment option for opioid withdrawal and related disorders of addiction. Although effective treatments exist for opioid addiction, painful and difficult withdrawal is one of the primary reasons why current treatment fails, and relapse occurs. By alleviating the symptoms associated with opioid withdrawal, Proniras hopes to help patients successfully discontinue opioid usage and sustain an opioid-free life. Proniras was formed in 2017 by Accelerator Life Science Partners.
- Industry Biotechnology
- Website https://proniras.com/
- LinkedIn https://www.linkedin.com/company/proniras-corporation/
ekko | $2,500,000 | (May 17, 2024)
Watershed Health | $13,600,000 | (May 17, 2024)
HEPHAISTOS-Pharma | $11,189,199 | (May 17, 2024)
Keyper | $4,000,000 | (May 17, 2024)
c/side | $1,700,000 | (May 17, 2024)
SINE Digital | $2,500,000 | (May 17, 2024)
Angel AI | $4,750,000 | (May 17, 2024)
InstaAstro | $2,300,000 | (May 17, 2024)
Fay | $25,000,000 | (May 16, 2024)